Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
42 USD | +0.19% | -1.22% | -29.84% |
Financials (USD)
Sales 2024 * | 822M | Sales 2025 * | 1.22B | Capitalization | 5.09B |
---|---|---|---|---|---|
Net income 2024 * | -122M | Net income 2025 * | 166M | EV / Sales 2024 * | 5.8 x |
Net cash position 2024 * | 317M | Net cash position 2025 * | 815M | EV / Sales 2025 * | 3.51 x |
P/E ratio 2024 * |
-42.5
x | P/E ratio 2025 * |
34.8
x | Employees | 704 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.7% |
Latest transcript on Apellis Pharmaceuticals, Inc.
1 day | +0.19% | ||
1 week | -1.22% | ||
Current month | -4.96% | ||
1 month | -18.95% | ||
3 months | -38.94% | ||
6 months | -12.30% | ||
Current year | -29.84% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 54 | 09-09-24 | |
Cedric Francois
FOU | Founder | 51 | 09-09-24 |
Timothy Sullivan
DFI | Director of Finance/CFO | 53 | 17-09-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Alec Machiels
FOU | Founder | 51 | 09-09-24 |
Director/Board Member | 65 | 13-06-30 | |
Andrew Dunlop
BRD | Director/Board Member | 52 | 10-02-28 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.61% | 0 M€ | 0.00% | - | |
0.45% | 0 M€ | 0.00% | - | |
0.19% | 4 M€ | +20.15% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-16 | 42 | +0.19% | 2,206,209 |
24-05-15 | 41.92 | +1.75% | 1,021,126 |
24-05-14 | 41.2 | -4.21% | 1,454,753 |
24-05-13 | 43.01 | +2.43% | 1,153,471 |
24-05-10 | 41.99 | -1.25% | 979,770 |
Delayed Quote Nasdaq, May 16, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-29.84% | 5.09B | |
-1.23% | 91.42B | |
+3.16% | 41.08B | |
-11.10% | 34.26B | |
+53.99% | 25.27B | |
-9.41% | 12.81B | |
-12.25% | 11.6B | |
-44.00% | 11.42B | |
+5.77% | 9.16B | |
-6.90% | 8.22B |
- Stock Market
- Equities
- APLS Stock